Ameriprise’s Eli Lilly LLY Stock Holding History

Ameriprise’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,500	Closed	-$3.47M	–	4099
2024 Q4	$3.47M	Buy	4,500 +1,700	+61%	+$1.41M	﹤0.01%	2617
2024 Q3	$2.48M	Buy	+2,800	New	+$2.52M	﹤0.01%	2799

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's LLY Position: Q2 2026 in Review

Ameriprise increased its Eli Lilly (LLY) stake by 0.41% in Q2 2026, buying an estimated $12.5M and bringing the position to 2,996,669 shares worth $3.6B. The position accounts for 0.73% of the portfolio, ranked #16.

Ameriprise first reported a position in LLY in Q2 2013 and has held it in 53 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Ameriprise held 2,996,669 shares of Eli Lilly worth $3.6B as of Q2 2026.
Ameriprise bought 12,277 Eli Lilly shares in Q2 2026, an estimated $12.5M.
Eli Lilly made up 0.73% of Ameriprise's portfolio in Q2 2026, its #16 holding.
Ameriprise first reported a position in Eli Lilly in Q2 2013 and has held it in 53 quarters since.
4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.